C12orf25 Inhibitors
Chemical inhibitors of C12orf25 can affect the function of this protein by targeting various signaling pathways and kinases that it may be involved in or regulated by. Staurosporine, a broad-spectrum protein kinase inhibitor, can inhibit multiple kinases that phosphorylate C12orf25, which is necessary for its activation and function. Similarly, Bisindolylmaleimide I, which specifically inhibits protein kinase C (PKC), can reduce C12orf25 activity by preventing PKC-mediated phosphorylation if C12orf25 is a substrate for PKC. LY294002 and Wortmannin are inhibitors of phosphoinositide 3-kinases (PI3K), and their action can lead to reduced C12orf25 activity by disrupting PI3K-dependent signaling pathways that may involve C12orf25. Additionally, Rapamycin, targeting the mTOR kinase within the PI3K/Akt/mTOR pathway, can inhibit downstream processes that include C12orf25, thereby reducing its activity.
Further, PD98059 and U0126, both selective inhibitors of MEK, can suppress the MAPK/ERK pathway, leading to reduced C12orf25 activity if the protein operates downstream of this pathway. SB203580, which selectively inhibits p38 MAP kinase, can also lead to reduced activity of C12orf25 if it is part of the p38 MAPK signaling cascade. Inhibition of c-Jun N-terminal kinase (JNK) by SP600125 can affect C12orf25 activity if it is involved in JNK signaling pathways. Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK), and by inhibiting ROCK, it can affect C12orf25 if ROCK signaling regulates the protein's activity. PP2, a selective inhibitor of Src family tyrosine kinases, can inhibit C12orf25 by disrupting Src kinase signaling pathways that may regulate the protein. Lastly, NF449, which selectively inhibits the Gs-alpha subunit of G proteins, can affect C12orf25 activity by altering signaling pathways regulated by the Gs-alpha subunit.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits a broad range of protein kinases, which could include kinases that phosphorylate C12orf25, leading to its functional inhibition by preventing essential phosphorylation events that are crucial for C12orf25's activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I is a specific inhibitor of protein kinase C (PKC). By inhibiting PKC, it would inhibit any PKC-mediated phosphorylation of C12orf25, if C12orf25 activity is dependent on PKC-dependent phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If C12orf25 is involved in PI3K-dependent signaling pathways, inhibition of PI3K would lead to a decrease in C12orf25 activity by disrupting those pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in the PI3K/Akt/mTOR pathway. Inhibition of mTOR would lead to reduced activity of any downstream effectors or processes that involve C12orf25, thereby inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream in the MAPK/ERK pathway. Inhibition of MEK, and consequently the MAPK/ERK pathway, would lead to reduced activity of C12orf25 if it is a downstream effector in this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that prevents activation of the MAPK/ERK pathway. By inhibiting this pathway, it would lead to functional inhibition of C12orf25 if C12orf25 requires MAPK/ERK signaling for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 MAP kinase would result in functional inhibition of C12orf25 if it is involved in the p38 MAPK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK). By inhibiting JNK, this compound would lead to functional inhibition of C12orf25 if C12orf25 operates as part of JNK signaling pathways. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). Inhibition of ROCK would lead to functional inhibition of C12orf25 if C12orf25's activity is regulated by ROCK signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting these kinases, PP2 would functionally inhibit C12orf25 if C12orf25's activity is regulated by Src kinase signaling pathways. | ||||||